Literature DB >> 7811865

Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin.

A L Forni1, N W Schluger, R B Roberts.   

Abstract

Between February and April 1991, six adults were admitted to the New York Hospital because of measles pneumonitis. The diagnosis was confirmed by serology and/or viral culture. Uncommon clinical features among patients with this diagnosis included thrombocytopenia, hepatitis, myositis, and hypocalcemia. All patients were markedly hypoxic (initial alveolar--arterial oxygen gradients while the patients were breathing room air, 40-61 mm Hg); four required support with mechanical ventilation. All patients received therapy with intravenous ribavirin (20-35 mg/[kg.d]) for 1 week. The respiratory status of five patients (one of whom was positive for human immunodeficiency virus [HIV]) who were treated early (days 2-5 of illness) promptly improved; all abnormal parameters eventually returned to baseline. Treatment of the sixth patient, who was presumed to be HIV-infected, was initiated on hospital day 22; this patient died of progressive oxygenation failure on day 38. We conclude that life-threatening measles pneumonitis in adults may be more common that previously appreciated, regardless of the patient's immune status. Therapy with intravenous ribavirin was well tolerated by our patients and was associated with reversal of respiratory compromise.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7811865     DOI: 10.1093/clinids/19.3.454

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  18 in total

1.  High-dose intravenous ribavirin therapy for subacute sclerosing panencephalitis.

Authors:  M Hosoya; S Shigeta; S Mori; A Tomoda; S Shiraishi; T Miike; H Suzuki
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  The Reemergence of Measles.

Authors:  C L Abad; N Safdar
Journal:  Curr Infect Dis Rep       Date:  2015-12       Impact factor: 3.725

Review 3.  Immune containment and consequences of measles virus infection in healthy and immunocompromised individuals.

Authors:  Sallie R Permar; Diane E Griffin; Norman L Letvin
Journal:  Clin Vaccine Immunol       Date:  2006-04

4.  Use of cotton rats to evaluate the efficacy of antivirals in treatment of measles virus infections.

Authors:  P R Wyde; D K Moore-Poveda; E De Clercq; J Neyts; A Matsuda; N Minakawa; E Guzman; B E Gilbert
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

5.  Controversies' clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages.

Authors:  George D Liatsos
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

Review 6.  Prevention and treatment recommendations for respiratory syncytial virus infection. Background and clinical experience 40 years after discovery.

Authors:  M G Ottolini; V G Hemming
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 7.  Measles Resurgence and Drug Development.

Authors:  Richard K Plemper
Journal:  Curr Opin Virol       Date:  2020-04-01       Impact factor: 7.090

Review 8.  Measles control--can measles virus inhibitors make a difference?

Authors:  Richard K Plemper; James P Snyder
Journal:  Curr Opin Investig Drugs       Date:  2009-08

9.  Fatal measles pneumonitis during Hodgkin's lymphoma.

Authors:  Benjamin Wyplosz; Marion Lafarge; Lélia Escaut; Jean-Baptiste Stern
Journal:  BMJ Case Rep       Date:  2013-10-08

Review 10.  Synergizing vaccinations with therapeutics for measles eradication.

Authors:  Richard K Plemper; Anthea L Hammond
Journal:  Expert Opin Drug Discov       Date:  2013-12-05       Impact factor: 6.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.